Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut
A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations is a phase 3 interventional study registered as NCT04923906 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 624 participants planned, started 2021-08-11 and due to reach its primary completion in 2024-06-18. Interventions recorded: Aumolertinib, Placebo Aumolertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAlmonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAENEAS
Shares Aumolertinib, Non-small-cell lung cancer.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Aumolertinib, Non-small-cell lung cancer.